Lord Penrose noted that the study on NANBH in the West of Scotland neither provided a basis on which the prevalence of post-transfusion NANB Hepatitis could, or should, have been drawn, nor indicated the potential value of ALT surrogate testing, or a basis for assessing that value. Read more about Lord Penrose noted that the study on NANBH in the West of Scotland neither provided a basis on which the prevalence of post-transfusion NANB Hepatitis could, or should, have been drawn, nor indicated the potential value of ALT surrogate testing, or a basis for assessing that value.
In a letter to The Lancet, Dr Gillon and colleagues called for a study of acute post-transfusion NANB Hepatitis in the UK and stated that surrogate screening was not justified at the time. Read more about In a letter to The Lancet, Dr Gillon and colleagues called for a study of acute post-transfusion NANB Hepatitis in the UK and stated that surrogate screening was not justified at the time.
An article in Transfusion by Wicks et al highlighted the drawbacks of both ALT and anti-HBc screening, and proposed greater medical education and more restrained blood usage to minimise new post-transfusion NANBH cases. Read more about An article in Transfusion by Wicks et al highlighted the drawbacks of both ALT and anti-HBc screening, and proposed greater medical education and more restrained blood usage to minimise new post-transfusion NANBH cases.
An article published in the Annals of Internal Medicine considered the role of anti-HBc as a surrogate, suggesting that the incidence of NANBH might have been reduced by about one third through anti-HBc screening. Read more about An article published in the Annals of Internal Medicine considered the role of anti-HBc as a surrogate, suggesting that the incidence of NANBH might have been reduced by about one third through anti-HBc screening.
Dr Gunson was asked in his court evidence if all the material showed that the introduction of ALT screening would have a beneficial effect if one looked at the concept of minimal risk for the recipient, if the the material was to that effect? Dr Gunson responded, "yes, it would reduce the risk to the recipient." Read more about Dr Gunson was asked in his court evidence if all the material showed that the introduction of ALT screening would have a beneficial effect if one looked at the concept of minimal risk for the recipient, if the the material was to that effect? Dr Gunson responded, "yes, it would reduce the risk to the recipient."
Dr Gunson stated in his court evidence that he had failed to secure a study of donor recipients around 1983, he said, "I was trying to generate it [data] and seemed to be blocked at every stage." Read more about Dr Gunson stated in his court evidence that he had failed to secure a study of donor recipients around 1983, he said, "I was trying to generate it [data] and seemed to be blocked at every stage."
In oral evidence to the Inquiry, Dr Brian McClelland agreed with the description of "decision paralysis" in relation to the situation with introduction of surrogate screening and undertaking of the respective study from the early 1980s through to the end of 1988. Read more about In oral evidence to the Inquiry, Dr Brian McClelland agreed with the description of "decision paralysis" in relation to the situation with introduction of surrogate screening and undertaking of the respective study from the early 1980s through to the end of 1988.
In oral evidence to the Inquiry, Dr Brian McClelland explained that the letter "Testing blood donors for Non-A, Non-B Hepatitis: irrational, perhaps, but inescapable" published in the Lancet was written partly out of extreme frustration at the fact that the appropriate epidemiological studies with donors and recipients had repeatedly not been done. Read more about In oral evidence to the Inquiry, Dr Brian McClelland explained that the letter "Testing blood donors for Non-A, Non-B Hepatitis: irrational, perhaps, but inescapable" published in the Lancet was written partly out of extreme frustration at the fact that the appropriate epidemiological studies with donors and recipients had repeatedly not been done.
In oral evidence to the Inquiry, Dr Brian McClelland accepted that nothing had really moved on since the beginning of the 1980s in relation to NANBH surrogate screening study. Read more about In oral evidence to the Inquiry, Dr Brian McClelland accepted that nothing had really moved on since the beginning of the 1980s in relation to NANBH surrogate screening study.
In oral evidence to the Inquiry, Dr Brian McClelland explained that ALT levels was only a small element of his proposal for a comprehensive study. Read more about In oral evidence to the Inquiry, Dr Brian McClelland explained that ALT levels was only a small element of his proposal for a comprehensive study.